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The majority of patients with pancreatic ductal adenocarcinoma (PDAC) are diagnosed with advanced 
stage disease and survive less than 12 months. Biomarkers enabling earlier diagnosis are sorely 
needed. Serum biomarker discovery studies tend to use samples from diagnosed patients, meaning 
current research efforts are potentially missing critical changes occurring in the months and years 
prior to diagnosis. Additionally a high proportion of PDAC patients are either hyperglycaemic or 
diabetic. The impact of diabetes on circulating biomarkers is poorly understood. Here we 
demonstrate, in serum taken up to 4 years prior to a PDAC diagnosis, that circulating TSP-1 levels 
are significantly reduced up to 24 months prior to diagnosis and low serum TSP-1 levels in PDAC 
patients are significantly associated with diabetes mellitus. Early detection strategies could benefit 
from including TSP-1. Future studies investigating biomarkers for pancreatic cancer detection should 





Purpose: Identification of serum biomarkers enabling earlier diagnosis of pancreatic ductal 
adenocarcinoma (PDAC) could improve outcome. Serum protein profiles in patients with pre-clinical 
disease and at diagnosis were investigated.  
Experimental Design: Serum from cases up to 4 years prior to PDAC diagnosis and controls 
(UKCTOCS,n=174) were studied, alongside samples from patients diagnosed with PDAC, chronic 
pancreatitis, benign biliary disease, type 2 diabetes mellitus and healthy subjects (n=298). iTRAQ 
enabled comparisons of pooled serum from a test set (n=150). Validation was undertaken using MRM 
and/or western blotting in all 472 human samples and samples from a KPC mouse model.  
Results: iTRAQ identified thrombospondin-1 (TSP-1) as reduced preclinically and in diagnosed 
samples. MRM confirmed significant reduction in levels of TSP-1 up to 24 months prior to diagnosis. 
A combination of TSP-1 and CA19-9 gave an AUC of 0.86, significantly outperforming both markers 
alone (0.69 & 0.77 respectively; P<0.01). TSP-1 was also decreased in PDAC patients compared to 
healthy controls (P<0.05) and patients with benign biliary obstruction (P<0.01). Low levels of TSP-1 
correlated with poorer survival, pre-clinically (P<0.05) and at clinical diagnosis (P<0.02). In PDAC 
patients, reduced TSP-1 levels were more frequently observed in those with confirmed diabetes 
mellitus (P<0.01). Significantly lower levels were also observed in PDAC patients with diabetes 
compared to individuals with type 2 DM (P=0.01). 
Conclusions: Circulating TSP-1 levels decrease up to 24 months prior to diagnosis of PDAC and 
significantly enhance the diagnostic performance of CA19-9. The influence of diabetes mellitus on 




For the majority of patients, pancreatic ductal adenocarcinoma (PDAC) goes undetected until it is at 
an advanced stage. Symptoms, such as obstructive jaundice, weight loss or pain often manifest late 
in the course of the disease when effective treatment options are limited. Consequently, overall 
survival is poor (1). CA19-9, the only biomarker in routine use for the management of pancreatic 
cancer (2, 3) has a number of limitations including lack of expression in ~5% of the population, and 
elevation in related diseases including chronic pancreatitis and obstructive jaundice (2, 4). Alternative 
biomarkers that can facilitate earlier diagnosis are actively sought (5, 6).  
To date, PDAC serum biomarker discovery work has almost exclusively used samples taken following 
diagnosis. Serum protein levels in these samples may not accurately reflect changes occurring in the 
months or years prior to diagnosis. To explore alterations in serum proteins that occur pre-clinically, 
we performed biomarker discovery using samples collected as part of the prospective cohort ‘United 
Kingdom Collaborative Trial of Ovarian Cancer Screening’ (UKCTOCS; www.ukctocs.org.uk/ (7, 8)). 
The nested cohort of samples analysed here were from women who were subsequently diagnosed 
with pancreatic cancer. We included samples taken up to 48 months prior to diagnosis of pancreatic 
cancer, along with control samples, matched for date of donation and the centre at which samples 
were donated.  
For biomarker discovery we used isobaric tags for relative and absolute quantification (iTRAQ), which 
allows for the simultaneous accurate, precise and reproducible quantification of proteins across 
several samples (9, 10). For validation we used multiple reaction monitoring (MRM), a mass 
spectrometry (MS)-based approach, which provides an alternative to immune-based protein 
quantification. MRM enables the detection and precise quantification of predetermined proteins in 
complex mixtures (11) and is capable of accurately discriminating between protein isoforms.  
We discovered significantly reduced levels of serum Thrombospondin-1 levels pre-clinically, during a 
period of 24 months prior to diagnosis with PDAC, and at diagnosis of PDAC. Importantly, we 
demonstrated a significant relationship between TSP-1 levels and diabetes mellitus in PDAC patients, 






Blood was obtained, with ethically approved informed written consent from two independent sources; 
UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS; ref.05/Q0505/57) and National 
Institute for Health Research Liverpool Pancreas Biomedical Research Unit (PBRU; ref11/NM/0083 
and 08/H1005/1). The UKCTOCS study set comprised serum from women recruited to UKCTOCS 
between 2001 and 2005(12) who went on to develop pancreatic cancer and time matched controls. 
The samples were subcategorised as follows; 0-6 months pre-diagnosis (n=30 cases, 30 controls), 
>6-12 months (n=17 cases, 17 controls), >12-24 months (n=17 cases, 17 controls), >24-36 months 
(n=11 cases, 11 controls) and >36-48 months (n=12 cases, 12 controls). In total, 174 UKCTOCS case 
samples from 76 individuals were used in the study. This included serial samples from 26 individuals. 
Two independent PBRU sets were analysed. The first PBRU set (n=199) consisted of 98 patients with 
histologically confirmed PDAC, 39 patients with chronic pancreatitis (CP), 20 with jaundice due to gall 
stones (benign biliary obstruction, BBO) and 42 healthy control individuals (HC). PDAC patients were 
further subcategorised into those with low bilirubin levels (49 patients, <20 µmol/L; upper level of 
normal for our Centre) and high bilirubin levels (49 patients, >20 µmol/L). To determine levels of TSP-
1 in individuals with type 2 diabetes mellitus (DM), a second independent PBRU cohort (n=99) was 
analysed. This included 54 patients with histologically confirmed PDAC, 18 patients with chronic 
pancreatitis (CP), 14 healthy control individuals (HC) and 13 patients with long-term (for 5 or more 
years) type 2 DM. Of the PDAC and CP patients, 26 and 9 respectively had confirmed diabetes. The 
clinical characteristics of the study populations are provided in Table 1A & B.  
Sample collection 
UKCTOCS blood samples were collected and processed throughout the trial according to a 
standardised SOP (8, 13). Blood was taken in Greiner gel tubes (8 mL separation tubes; Greiner Bio-
one 455071, Stonehouse UK) at one of 13 trial centres, transported overnight at ambient temperature 
to a central laboratory, centrifuged at 4,000 rpm for 10 minutes and serum aliquoted and stored in 
liquid nitrogen. All UKCTOCS blood samples used in this study were processed within 20 hours of 
venepuncture. PBRU blood samples were collected in Sarstedt Monovette tubes (Sarstedt Ltd, 
Leicester, UK), placed at 4 °C for 15 min and centrifuged at 800 ×g for 10 min at 4°C. Serum was 
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stored in aliquots at − 80 °C. Preoperative total serum bilirubin (μmol/L) (Roche Modular SWA) and 
CA19−9 levels were measured in hospital Clinical Biochemistry Departments, or by CA19-9 ELISA 
(Human Pancreatic & GI Cancer ELISA Kit, Alpha Diagnostics International, San Antonio, Texas, 
USA).  
Murine sample collection 
Animals were treated in accordance with European and institutional guidelines (Legislative Order No. 
116/92). 129SvJae/B6 H-2Db mice carrying mutated KrasG12D and Trp53R172H under the endogenous 
promoter, and flanked by Lox-STOP-Lox cassettes (LSL-KrasG12D/+ and LSL-Trp53R172H/+). Serum 
samples were collected from 10 LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) mice and 9 age-
matched control (LSL-Trp53R172H/+;Pdx-1-Cre) mice via cardiac bleed under isofluorane gaseous 
anaesthesia. Blood was collected at 6 weeks, 2 months and 3-6 months and centrifuged at 1000x g 
for 20 minutes at room temperature. Serum was collected, snap frozen (in liquid nitrogen) and stored 
at -80°C in 60ul aliquots. Mice were surgically and pathologically examined to confirm the presence of 
pancreatic tumours and metastases.  
iTRAQ analysis 
An iTRAQ 8-plex experiment using pooled, delipidated and high abundance protein-depleted serum 
from a discovery subset of pre-diagnosis UKCTOCS samples; 0-6 months cases & controls (n=18 per 
group), >6-12 months cases & controls (n=17 per group) and PBRU samples; PDAC non obstructed 
(n=20), PDAC obstructed (n=20), CP (n=20) and HC (n=20) (total n= 150), was analysed as 
described previously(10, 14) on a QSTAR-Pulsar i Hybrid Mass Spectrometer (AB Sciex, 
Framingham, USA). Two replicate analyses were also performed on a Triple TOF-5600 (AB Sciex) as 
described(15). Data were analysed using ProteinPilot software (Version 4.0, AB Sciex). The clinical 
characteristics of the study subset populations are provided in Supplementary Table S1. 
Ingenuity Pathway Analysis 
A protein list of significantly altered proteins generated from our iTRAQ data was uploaded into 
Ingenuity Pathway Analysis (IPA) software server (http://www.ingenuity.com). The iTRAQ dataset was 
converted from iTRAQ ratio to fold change and a significance cut-off of P-value <0.05 was utilised. 




Multiple reaction monitoring was carried out on all 150 samples (UKCTOCS n=70; PBRU n=80) used 
in iTRAQ discovery alongside 196 additional validation samples (UKCTOCS n=104; PBRU n=92).  
MRM analysis on single serum samples was performed on a 5500 QTRAP mass spectrometer 
(ABSciex, Framingham, USA) coupled with an Ultimate 3000 HPLC (Dionex-ThermoScientific, UK). 
Two target peptides were chosen for TSP-1 and three optimum transitions for each peptide were 
determined empirically using synthetic peptides (Peptide Protein Research Limited, Fareham, UK; 
See Supplementary Table S2). Corresponding stable-isotope labelled versions of each peptide (C13, 
N15 labelled leucine), were used as internal standards with three transitions selected for each. 
Standard curves (7 point) were prepared with each peptide from 0.125 fmol to 10 fmol (on-column) in 
a peptide digest from human serum (diluted to ~0.25 µg/mL with 2% acetonitrile + 0.1% formic acid), 
with subsequent regression analysis showing acceptable linearity (r2 ≥ 0.95). Serum samples (1 µL), 
digested overnight with trypsin, were diluted 1 in 6 with a solution containing 2% acetonitrile, 0.1% 
formic acid, spiked with the internal standard peptides (to give a final concentration of 50 fmol) and 
ionized using a spray voltage of 5500 V and a source temperature of 475 °C. Analyzer parameters 
were optimized for each peptide/transition pair to ensure maximum selectivity, dwell time was 50 ms. 
Peptide separation was achieved with a Hypersil Gold 50 x 1 mm, 1.9 µm, 175 Å column, using a 20 
min gradient, at a flow rate of 100 µL min-1, with buffer A (0.1% formic acid) and Buffer B (95% 
acetonitrile + 0.1% formic acid). The LC gradient comprised the following: 2% buffer B for 2 min, 
ramped to 10% buffer B in 0.1 min, 40% buffer B in 10 min, 80% buffer B in 0.1 min held for 3 min, 
and 2% buffer B in 0.1 min held for 5 min. Prior to analysing each batch of serum samples, 
chromatographic performance and mass spectrometric stability were evaluated using a tryptic peptide 
mixture of beta-galactosidase (Sigma Aldrich, Dorset, UK). Three aliquots of each serum sample was 
analysed, each in duplicate with 2 MRM transitions measured for each of 2 peptides (6 readings for 
each of 4 MRM transitions), generating a total of 24 MRM readings per sample. The acquired MRM 
.wiff files were analysed using MultiQuant™ software (Version 2.1), where peak-area was determined 
for each peptide transition and calculated concentrations determined using the software-generated 
standard curves. Percentage coefficients of variance (%CV) for each of the 4 MRM transitions were 
calculated and those over 25% were excluded. The average CV for the UKCTOCS samples was 
17.7% between the 4 MRM transitions and 11.4% for the PBRU samples. 
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Western Blot Analysis 
For western blotting, individual serum samples were diluted 1:10 and 4 µL of each sample analysed 
using anti-TSP-1 A6.1 mouse monoclonal antibody (1:400; Thermoscientifc, Hemel Hempstead, UK). 
A standard comprising 20 pooled HC samples was used at three different dilutions per gel, allowing 
comparison and quantification across blots. Protein was separated on Any kD™ Mini-PROTEAN® 
TGX™ Precast gels (Biorad, Hemel Hempstead, UK), transferred onto PVDF membranes and 
blocked for 1 h in 5% milk/PBS Tween (PBST). Primary antibody was incubated overnight at 4 °C in 
5% milk/PBST. Membranes were washed with PBST and incubated with HRP-conjugated secondary 
antibodies diluted in 5% milk/PBST. Bands were visualised with enhanced chemiluminescence 
developed with X-ray film. Densitometry was performed (Kodak MI SE software, Carestream Health), 
and protein quantities recorded relative to HC standards. All samples were analysed at least in 
triplicate.  
Immunohistochemistry 
Formalin fixed paraffin embedded (FFPE) tissue from 49 PDAC patients was used to construct a 
tissue microarray (TMA). Sections were deparaffinised and antigen retrieval was performed using a 
PT Link (Dako) with Target Retrieval Solution, High pH (Dako). Anti-TSP-1 A6.1 mouse monoclonal 
antibody (1:100; Thermoscientific) was incubated at room temperature for one hour. Positively stained 
tumour cells and tumour-associated stroma were identified by a specialist histopathologist.  
 
Data analysis 
Statview V.5.01 (SAS Institute Inc., Cary, North Carolina) and Medcalc software (Version 13, 
Mariakerke, Belgium) were used. iTRAQ data were compared using the Mann Whitney U test. MRM 
and western data were analyzed using the two-tailed Mann Whitney U test and diagnostic accuracy 
compared by Receiver Operating Characteristic (ROC) Analyses. Patient immunohistochemistry data 
were compared with clinicopathological parameters using Fisher’s exact, Pearson’s chi-squared and 





No differences in time to centrifugation were observed between case and control samples in any of 
the UKCTOCS time to diagnosis groupings. A significant difference was noted in median age of the 
36-48 month groups (P=0.01), however a Spearman's rank correlation for comparison of age and 
TSP-1 levels showed no significant correlation (Spearman's rank correlation coefficient rho=0.0.03, 
P=0.674). Likewise in the PBRU samples a significant difference was seen in age between cancer 
patients and controls (P=0.002) but no significant correlation was seen when Spearman’s rank was 
performed (Spearman's rank correlation coefficient rho=-0.07, P=0.328). No gender differences in 
TSP-1 were found in the PBRU cohort. 
Serum iTRAQ analysis 
Pooled sera from pre-diagnosis UKCTOCS samples; 0-6 months cases & controls, >6-12 months 
cases & controls and PBRU samples; PDAC non-obstructed, PDAC obstructed, CP and HC, were 
compared in an 8-plex iTRAQ experiment. To increase the sensitivity of protein detection, high 
abundance proteins were depleted from pooled samples prior to labelling with iTRAQ tags. Since the 
presence of jaundice can alter serum protein levels (14, 16), PDAC patients were split into those with 
and those without obstructive jaundice. The experiment was performed three times, yielding a total of 
225 proteins identified using at least two peptides at 95% confidence. Protein expression differences 
between groups were assessed by comparing the relative intensity of reporter ions released from 
each labelled peptide and calculating protein ratios. A representative dataset is provided in 
Supplementary Table S3. 
 
TSP-1 levels are decreased in pooled pre-diagnosis and diagnosed PDAC samples 
We sought markers that were altered in the lead into pancreatic cancer diagnosis and in diagnosed 
pancreatic cancer patients irrespective of jaundice. Using IPA-Biomarker we compared iTRAQ data 
from pre-diagnostic sample pools versus their respective control pools, along with non-obstructed 
PDAC patient pools versus HC pools and CP pools, to generate a shortlist of candidates. The high 
abundance proteins targeted in our depletion protocols were excluded, along with proteins previously 
characterised by our group (10, 17). TSP-1 emerged as a candidate biomarker as its levels were 
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reduced with significant fold change differences in case samples in the 0-6 month and 6-12 month 
time groups prior to diagnosis as well as in PDAC versus HC PBRU samples taken at diagnosis 
(Table 2).  
 
Validation of TSP-1 in individual pre-diagnosis and diagnosed PDAC samples  
For the accurate quantification of serum TSP-1 in individual serum samples (n=346), we used a LC-
MS/MS system, operated in MRM mode with stable isotope labelled internal standards. The two 
peptides chosen were unique for TSP-1 (Supplementary Figure S1A) allowing unambiguous 
discrimination from other thrombospondin family members. The lower limit of detection of the assay 
was 0.1 fmol/µL and where TSP-1 fell below detection, the level was arbitrarily assigned a value of 
zero. When all 87 pre-diagnostic cases, covering up to 48 months prior to diagnosis, were compared 
with their time-matched controls, TSP-1 levels were significantly lower in cases versus (P<0.001; 
Figure 1 A). Separating samples into their individual time to diagnosis groups revealed TSP-1 levels 
were significantly reduced compared to time matched controls in the 0-6 month, (P =0.04), 6-12 
month (P=0.004) and 12-24 month (P=0.03) cases (Figure 1 B). Significantly lower levels of TSP-1 
were observed in PDAC patients in the presence (P=0.02) and in the absence (P=0.03) of jaundice 
compared to healthy subjects and compared to patients experiencing biliary obstruction due to 
gallstones (BBO: P=0.01 and P=0.05 respectively) (Figure 1 C). By contrast, no significant difference 
in TSP-1 level was established between patients with CP (Figure 1 C). Furthermore, we could not 
establish any difference between levels of TSP-1 in resectable PDAC cases versus non resectable 
cases (Supplementary Figure S2).  
Western blotting using a mouse monoclonal (A6.1) antibody for TSP-1 revealed a single band in 
human foreskin fibroblast (HFF) cells, which was not detected following treatment with TSP-1-
targeting siRNA (Supplementary Figure S1B). The banding pattern obtained in pre-diagnosis and 
diagnosed serum samples with this antibody is shown in Supplementary Figure S1B. Weak, although 
significant correlations for TSP-1 in MRM and western measures were observed in pre-diagnosis 
samples (n=128; Spearman's rank correlation coefficient rho=0.29, P=0.005) and diagnosed samples 
(n=199; Spearman's rank correlation coefficient rho=0.48, P=0.0001). Semi–quantitative western 
analysis confirmed a significant decrease in the 6-12 month pre-diagnosis samples (n=17) versus 
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controls (n=17, p=0.03) and in diagnosed PDAC patients in the presence (n=48; p=0.001) and 
absence (n=49; p=0.0007) of jaundice compared to healthy subjects (n=42). 
Corresponding CA19-9 data for the pre-diagnosis and diagnosed PDAC samples are presented in 
Supplementary Figures S2 A and B respectively. CA19-9 levels were significantly up-regulated in in 
the 0-6 month pre-diagnosis cases compared to controls (p=0.001), in the 6-12 month pre-diagnosis 
cases compared to controls (p=0.04), in patients with PDAC in the presence and absence (P=0.0001) 
of biliary obstruction compared to HC (P=0.001 and P=0.0001, respectively) and CP (both P=0.0001), 
consistent with our previous observations (12).  
Validation of TSP-1 in murine samples  
Low TSP-1 serum levels were observed in LSL-KrasG12D/+;LSL-Trp53R172H/+;Pdx-1-Cre (KPC) mice 
with cancer, compared to KPC mice with high or low grade PanIN and compared to age-matched 
control (LSL-Trp53R172H/+;Pdx-1-Cre) mice (Figures 1 D and E).  
Low TSP-1 levels correlate with poor outcome 
Next we examined the relationship between circulating TSP-1 levels and survival. For this analysis, 
TSP-1 levels equal to the 25th percentile (0.00 fmol/µL) were classified as low with the remaining 
values classified as high. The preclinical levels of TSP-1, up to 24 months prior to diagnosis were 
associated with a significantly reduced survival time from diagnosis (Figure 2 A; logrank χ21=3.7 
p=0.05). Only diagnosed patients with resectable disease (n=75) were included and the median 
survival of these patients with low circulating TSP-1 was significantly lower than those with high TSP-
1 (Figure 2 B; logrank χ21=4.27 P=0.04).  
Ability to distinguish pre-diagnosis cases from controls 
While our work was in progress, Nie et al (18) reported that TSP-1 provided AUCs of 0.78 and 0.83 
for the discrimination of clinically diagnosed PDAC from HC and CP respectively. In samples up to 24 
months prior to diagnosis (Figure 2 C), we found that TSP-1 distinguished cases from controls with an 
AUC of 0.69. During this time period, CA19-9 yielded an AUC of 0.77.  The combination of both 
markers achieved a significantly higher AUC of 0.85 (p=0.02; Figure 2 C).  
TSP-1 levels do not relate to platelet count 
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TSP-1 was identified as a molecule released from platelets in response to thrombin treatment (19). 
Concerned that fluctuations in circulating TSP-1 may reflect changes in blood platelet levels, we 
correlated PDAC patient platelet count (n=96 PDAC patients) with TSP-1 levels. The median platelet 
count was 293 x109/L, but was significantly elevated in patients with advanced cancer (n=20; count 
344 x109/L), compared to resectable cancer (n=76; count 277 x109/L; p=0.02). No significant 
correlation was detected between TSP-1 levels and platelet count in either resectable (Spearman 
Rank rho= 0.01, p=0.88) or in advanced patients (rho= -0.13, p=0.57). 
TSP-1 serum levels are associated with diabetes mellitus 
Although TSP-1 levels were significantly lower in cancer patients than controls (Figure 1 C), not all 
cancer patients had reduced levels. We therefore hypothesised that the marker may be regulated in a 
sub-set of patients only and examined for associations between circulating TSP-1 levels and 
clinicopathologic parameters, separating PDAC patients into low or high for TSP-1 based on 
circulating TSP-1 values < or ≥ the median (0.267 fmol/µL). Associations could not be established 
between gender, age at surgery, presence of obstructive jaundice, operable versus advanced, 
resection margin status, T stage or nodal status (Supplementary Table S4). However, the presence of 
diabetes in PDAC patients was significantly associated with TSP-1 (Chi-squared test, P=0.02, 
Supplementary Table S4). Examining this further, of 27 patients with confirmed diabetes, 19 (70.3%) 
had less than the median level of TSP-1 (14 of those patients had undetectable TSP-1). By contrast, 
of the remaining 71 patients without confirmed diabetes, only 30 (42.2%) had less than the median 
serum TSP-1 level (Chi-squared test, P=0.01). Upon separating our clinically diagnosed PDAC 
patients into those with- and without-diabetes, a significant reduction in TSP-1 levels were observed 
for the PDAC patients with diabetes compared to all other control groups (Figure 3A).  Finally, given 
the correlation between diabetes and TSP-1, we examined whether diabetes was associated with 
outcome in this cohort, but no association was observed (Figure 3 B; logrank χ21=1.53 P=0.22).  
PDAC related diabetes often goes undiagnosed (20); it is therefore unsurprising that only 10% of 
UKCTOCS cases were recorded as having diabetes. Since a substantial number of UKCTOCS cases 




TSP-1 serum levels are lower in PDAC patients with diabetes compared to individuals with 
long-term type 2 diabetes mellitus 
Measurement of TSP-1 levels by western blot in an independent cohort confirmed our previous 
observation that significantly lower levels of TSP-1 are present in PDAC patients with diabetes 
compared to PDAC patients without diabetes (P=0.002), healthy subjects (P<0.0001) and CP patients 
(P=0.05); Figure 4). Significantly lower levels were also observed in PDAC patients with diabetes 
compared to individuals with long term type 2 DM (P=0.01). 
TSP-1 tumour expression is not associated with diabetes mellitus  
To determine whether tumour levels of TSP-1 were associated with diabetes mellitus, a PDAC TMA 
was stained for TSP-1 (Figure 3 C). Tumour cell staining was observed in 7/49 cases (14%) while 8 
patients (16%) expressed TSP-1 in desmoplastic stroma. Two patients (4%) were positive for both 
tumour and stromal staining. Thirty-two (65%) patients lacked detectable tissue TSP-1 expression. 
Associations could not be established between TSP-1 expression and other clinicopathological 
parameters, including diabetes (Supplementary Table S5). This remained true when expression was 
categorised as either tumoural or stromal. 
 
Discussion  
Previous serum biomarker studies have carried out discovery work on samples taken from patients 
after a diagnosis of PDAC has been made (11, 29, 30, 31, 32), thereby potentially missing critical 
changes to the serum disease profile that occur months and years prior to diagnosis. Our study is 
virtually unique in that we have simultaneously subjected pre-clinical and clinical samples to a 
proteomic biomarker discovery protocol and identified a protein of interest, TSP-1, that appeared 
altered before and after diagnosis, highlighting its potential as an early biomarker. We used MRM in 
this study to verify these changes in individual serum samples as it afforded unequivocal identification 
and accurate quantification of TSP-1 by selecting peptides unique to the TSP-1 protein. We saw 
similar trends in reduction of TSP-1 levels using an antibody-based approach. However cross-
reaction between the antibody used in our study and TSP-2 cannot be ruled out (21) and might 
explain differences between MRM and western data. TSP-1 is a large secreted multimeric 
matricellular protein (22), whose role in cancer is controversial. TSP-1 has been described as anti-
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carcinogenic due to its potent anti-angiogenic properties, mediated in large part through binding to 
CD36 (fatty acid translocase; FAT) and CD47 (integrin-associated protein; IAP) and its role in 
activation of TGF-beta (23). Serum levels of TSP-1 are decreased in patients with prostate cancer 
(24) and lung cancer (25),(26), while plasma levels of TSP-1 are elevated in breast cancer patients 
(27). In pancreatic cancer, serum TSP-1 levels were found to be significantly increased in patients 
with unresectable cancer (28), although we could not establish any difference between levels in 
unresectable versus resectable pancreatic cancer patients. Our analysis of TSP-1 expression in 
pancreatic cancer tissue did not help explain the reduction in the circulating levels of TSP-1 in PDAC 
patients. Currently, we cannot propose a mechanism for our observations. 
As we have previously reported, the presence of jaundice, a late symptom in PDAC patients, can 
influence biomarker levels (14, 16). Potential markers that are not affected by jaundice are more likely 
to be indicative of early disease. We allowed for this here by separately analysing PDAC samples 
taken from diagnosed patients in the presence versus absence of jaundice. The reduction of TSP-1 
levels in patients’ serum, regardless of the presence of jaundice, distinguished it from previous 
candidates evaluated by our group (10) and made it an attractive candidate for early diagnosis. 
Consistent with our findings, others have reported lower circulating TSP-1 levels in PDAC patients 
compared to healthy controls (18, 28). Here we go further by showing significant reduction of TSP-1 
levels in patients up to 24 months prior to diagnosis of pancreatic cancer. We recently showed that 
CA19-9 discriminated preclinical PDAC cases from controls (12). Combining TSP-1 and CA19-9 
offered a significant improvement over either marker alone. Our analysis of serum from KPC mice 
provided evidence for a decrease in circulating TSP-1 in mice with PDAC, but not in mice with PanIN 
lesions. This raises the question as to whether the decreases in TSP-1 observed in pre-diagnostic 
UKCTOCS cases are occurring in a background of already formed PDAC. Further study is required to 
unravel this question. 
Upon separating our PDAC patients into those with and without diabetes we found that levels of TSP-
1 were significantly reduced in clinically diagnosed PDAC patients with diabetes compared to all 
control groups, including individuals with long-term type 2 DM. Our findings therefore suggest a link 
between reduced serum TSP-1 levels and PDAC-associated diabetes (type III C). Pannala et al. 
reported that 85% of PDAC patients have hyperglycaemia or diabetes with some 47% having 
16 
 
diabetes (20). In our study, only 27% of diagnosed PDAC patients had confirmed diabetes, which is 
likely to be an underestimate. TSP-1 has been shown to be an adipokine, associated with insulin 
resistance (29). Moreover, TSP-1-null mice are markedly glucose intolerant and have decreased 
glucose-stimulated insulin release and capacity for (pro)insulin biosynthesis, although they possess 
an increased beta-cell mass (30). This phenotype was attributed to the lack of activation of islet 
TGFβ-1 by endothelial-derived TSP-1. Failure of glucose regulation may occur before a rise in CA19-
9, perhaps explaining why TSP-1 adds to CA19-9 in discriminating early disease. More work is 
needed to uncover the true extent of the relationship between TSP-1 and diabetes in PDAC patients, 
and to determine whether TSP-1 might serve as a PDAC screening tool in individuals newly 
diagnosed with type 2 DM. Aggarwall et al. (31) reported elevated plasma levels of adrenomedullin in 
PDAC patients with new-onset DM compared to PDAC patients with normal fasting glucose and 
compared to non-cancer subjects with new-onset type DM. 
Limitations of this study include using pooled samples for iTRAQ profiling as this is sensitive to 
outliers and can lead to false positives. Extensive validation was therefore undertaken using both 
individual samples of the iTRAQ set and also independent samples. It is possible that the delay of 
processing in UKCTOCS samples may have led to the loss of some proteins. In addition, it was not 
possible to evaluate longitudinal preclinical alterations in TSP-1 as the number of UKCTOCS cases 
with available longitudinal samples was insufficient to adequately assess this. Finally, as mentioned 
above, the number of individuals with diabetes in our PBRU cancer cohort is likely to be 
underestimated, and accurate diabetes data were only available for a small number of UKCTOCS 
cases, preventing sensible evaluation of TSP-1 levels and diabetes in the preclinical setting.  
In conclusion, our study allowed a valuable appraisal of TSP-1 levels during the lead into pancreatic 
cancer diagnosis, demonstrating that its inclusion in diagnostic panels could have potential in early 
detection strategies. We have also highlighted the effect diabetes can have on the performance of 
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Table 1A). Patients Characteristics of UKCTOCS pre-diagnostic cases and controls for whole study 
set and 1B) Patients Characteristics of PBRU diagnosed PDAC samples and controls for whole study 
set. 
Table 2. IPA Biomarker Filter Analysis from iTRAQ data set. 
Figure 1. Detection of thrombospondin 1 (TSP-1) by MRM in (A) all pre-diagnostic samples versus 
controls, (B) in individual time to diagnosis groups, (C) in diagnosed samples and controls (PDAC obs 
= bilirubin >20µmol/L, presence of jaundice; PDAC non-obs = bilirubin <20µmol/L, absence of 
jaundice; CP = chronic pancreatitis, BBO = benign biliary obstruction, HC = healthy control) and (D) 
genetically engineered mice (PanIN = pancreatic intraepithelial neoplasia (pre-neoplastic lesion). Low 
grade = PanIN I or II, High grade = PanIN III). 
Figure 2. Survival curves for TSP-1 in (A) pre-diagnosis and (B) diagnosed patients (low levels =0.00 
fmol/µL, (C) Performance of TSP-1, based on MRM measurements, to discriminate 0-24 month pre-
diagnostic patients (n=64) from time matched controls (n=64). 
Figure 3. TSP-1 is associated with diabetes in diagnosed samples compared to all other groups (A), 
Diabetes mellitus does not relate to outcome (B), TSP-1 staining in PDAC tissue samples (C).  
Figure 4. Detection of thrombospondin 1 (TSP-1) by western analysis in an independent cohort of 
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High levels of TSP1 
Low levels of TSP1 
At risk 
25 14 9 4 2 0 
9 2 0 0 0 0 
p=0.05 
At risk 
46 27 12 6 0 
30 8 3 1 0 
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Table 1a) Patients Characteristics of UKCTOCS pre-diagnostic cases and controls for whole study set 
 0-6m 6-12m 12-24m 24-36m 36-48m
 cases ctrls cases ctrls cases ctrls cases ctrls cases ctrls 
n 30 30 17 17 17 17 11 11 12 12 



































































Abbreviations: ctrls - controls; IQR - interquartile range. 
Table 1b) Patients Characteristics of PBRU diagnosed PDAC samples and controls for whole study set 
  PBRU cohort 1 PBRU cohort 2































Gender F/M 28/21 26/23 20/22 20/19 5/15 16/12 9/17 7/7 7/6 3/6 2/7
Diabetes  14 13 n/a 5 3 - 26 - 13 - 9
Resection Margin R0 10 11 - - - 5 6 - - - -
 R1 24 26 - - - 16 14 - - - -
 U 3 2 - - - 1 - - - - -
 I 12 10 4 6
Staging IA 1 - - - - 2 1 - - - -
 IB - 1 - - - - - - - - -
 IIA 6 6 - - - 3 6 - - - -
 IIB 28 30 - - - 16 12 - - - -
 III/IV 12 10 - - - 4 7 - - - -
 U 2 2 - - - 1 - - - - -
Abbreviations: BBO - benign biliary obstruction; CP - chronic pancreatitis; F - female; HC – healthy control; I – Inoperable; IQR  -interquartile range;  M - male; obs – 
obstruction;  
PDAC - pancreatic ductal adenocarcinoma; U - unknown 
Table 2. IPA Biomarker Filter Analysis from iTRAQ data set 
 




case ‘v’ ctrls 
APOE apolipoprotein E -6.54 0.017 
HP haptoglobin 1.42 0.000 
KRT6B keratin 6B 3.56 0.039 
TSP-1 thrombospondin 1 -2.09 0.010 
6-12m  
case ‘v’ ctrls 
FN1 fibronectin 1 -1.08 0.000 
ICAM1 intercellular adhesion molecule 1 -1.51 0.004 
KRT6B keratin 6B -5.55 0.038 
SERPINA1 serpin peptidase inhibitor, clade A member 1 -1.21 0.002 
TSP-1 thrombospondin 1 -4.49 0.042 
PDAC non 
obs ‘v’ HC 
APOE apolipoprotein E 8.40 0.005 
CRP C-reactive protein, pentraxin-related 52.96 0.031 
FGA fibrinogen alpha chain -10.19 0.042 
FN1 fibronectin 1 -1.14 0.000 
HP haptoglobin -1.06 0.002 
ICAM1 intercellular adhesion molecule 1 35.65 0.003 
KRT6B keratin 6B -2.63 0.004 
LGALS3BP lectin, galactoside-binding, soluble, 3 binding protein 2.47 0.038 
MCAM melanoma cell adhesion molecule -4.29 0.001 
NCAM1 neural cell adhesion molecule 1 -2.13 0.030 
PLG plasminogen 2.75 0.013 
SERPINA1 serpin peptidase inhibitor, clade A member 1 1.29 0.008 
TSP-1 thrombospondin 1 -4.97 0.032 
PDAC non 
obs ‘v’ CP 
APOA1 apolipoprotein A-I 32.21 0.000 
APOE apolipoprotein E 32.81 0.000 
FGA fibrinogen alpha chain -24.66 0.007 
FN1 fibronectin 1 1.03 0.011 
HP haptoglobin -1.82 0.000 
ICAM1 intercellular adhesion molecule 1 42.46 0.003 
KRT6B keratin 6B -1.91 0.005 
MCAM melanoma cell adhesion molecule -4.29 0.001 
NCAM1 neural cell adhesion molecule 1 -1.26 0.033 
SERPINA1 serpin peptidase inhibitor, clade A member 1 1.20 0.000 
